1921
Volume 91, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Much of the basic clinical information about dengue infection comes from experimental human studies conducted in the 1920s and 1940s. Albert Sabin's original laboratory records from one such study were bequeathed to Duane J. Gubler. These records were reviewed and 150 experiments were included in our analyses. Persons were inoculated with dengue virus 1 (DENV-1) and DENV-2. Median fever duration was shorter in primary DENV-2 infections compared with DENV-1, although maximum temperature and severity of illness were comparable. At 1.5–9 months after primary infection, 20 persons were inoculated with the heterologous serotype. Only one person inoculated with a heterologous serotype at < 8 weeks showed development of a clinical infection with a maximum temperature of 38°C, and 7 (88%) of 8 persons inoculated with a heterologous serotype at 4–9 months post-primary infection showed development of fever. On average, persons had a shorter incubation period in secondary infection compared with primary infection.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0132
2014-12-03
2017-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/91/6/1203.html?itemId=/content/journals/10.4269/ajtmh.14-0132&mimeType=html&fmt=ahah

References

  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, , 2013. The global distribution and burden of dengue. Nature 496: 504507.[Crossref]
  2. Halstead SB, , 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239: 476481.[Crossref]
  3. Murphy BR, Whitehead SS, , 2011. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587619.[Crossref]
  4. Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, Hombach J, Farrar J, , 2013. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine 31: 26032609.[Crossref]
  5. Zompi S, Harris E, , 2012. Animal models of dengue virus infection. Viruses 4: 6282.[Crossref]
  6. Khor CC, Chau TN, Pang J, Davila S, Long HT, Ong RT, Dunstan SJ, Wills B, Farrar J, Van Tram T, Gan TT, Binh NT, Tri le T, Lien le B, Tuan NM, Tham NT, Lanh MN, Nguyet NM, Hieu NT, Van NV, Thuy TT, Tan DE, Sakuntabhai A, Teo YY, Hibberd ML, Simmons CP, , 2011. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet 43: 11391141.[Crossref]
  7. Bennett SN, Holmes EC, Chirivella M, Rodriguez DM, Beltran M, Vorndam V, Gubler DJ, McMillan WO, , 2003. Selection-driven evolution of emergent dengue virus. Mol Biol Evol 20: 16501658.[Crossref]
  8. Gubler DJ, Reed D, Rosen L, Hitchcock JR, Jr, 1978. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 27: 581589.
  9. Steel A, Gubler DJ, Bennett SN, , 2010. Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago. Virology 405: 505512.[Crossref]
  10. Sabin AB, , 1952. Research on dengue during World War II. Am J Trop Med Hyg 1: 3050.
  11. Siler JF, Hall MW, Hitchens AP, , 1926. Dengue: its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philipp J Sci 29: 1304.
  12. Simmons JS, John JHS, Reynolds FH, , 1931. Experimental studies of dengue. Philipp J Sci 44: 1247.
  13. Wahala WM, Silva AM, , 2011. The human antibody response to dengue virus infection. Viruses 3: 23742395.[Crossref]
  14. Rasmussen CE, Williams CK, , 2006. Gaussian Processes for Machine Learning. Boston, MA: MIT Press.
  15. Gubler DJ, Monath TP, , 1988. Dengue. , ed. The Arboviruses: Epidemiology and Ecology. Volume II. Boca Raton, FL: CRC Press, Inc., 223260.
  16. Simpson WM, , 1936. Artificial fever therapy of syphilis and gonococcic infections. Br J Vener Dis 12: 133166.
  17. Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, Ng LC, Lai YL, Yap GS, Li CS, Vasudevan SG, Ong A, , 2006. Early dengue infection and outcome study (EDEN): study design and preliminary findings. Ann Acad Med Singapore 35: 783789.
  18. Binh PT, Matheus S, Huong VT, Deparis X, Marechal V, , 2009. Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults. J Clin Virol 45: 276280.[Crossref]
  19. Ramos MM, Tomashek KM, Arguello DF, Luxemburger C, Quinones L, Lang J, Munoz-Jordan JL, , 2009. Early clinical features of dengue infection in Puerto Rico. Trans R Soc Trop Med Hyg 103: 878884.[Crossref]
  20. Chau TN, Anders KL, Lien le B, Hung NT, Hieu LT, Tuan NM, Thuy TT, Phuong le T, Tham NT, Lanh MN, Farrar JJ, Whitehead SS, Simmons CP, , 2010. Clinical and virological features of dengue in Vietnamese infants. PLoS Negl Trop Dis 4: e657.[Crossref]
  21. Low JG, Ong A, Tan LK, Chaterji S, Chow A, Lim WY, Lee KW, Chua R, Chua CR, Tan SW, Cheung YB, Hibberd ML, Vasudevan SG, Ng LC, Leo YS, Ooi EE, , 2011. The early clinical features of dengue in adults: challenges for early clinical diagnosis. PLoS Negl Trop Dis 5: e1191.[Crossref]
  22. Biswas HH, Ortega O, Gordon A, Standish K, Balmaseda A, Kuan G, Harris E, , 2012. Early clinical features of dengue virus infection in nicaraguan children: a longitudinal analysis. PLoS Negl Trop Dis 6: e1562.[Crossref]
  23. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ, , 2010. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 12: 157164.[Crossref]
  24. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, Yoon IK, Gibbons RV, Burke DS, Cummings DA, , 2013. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 10: 20130414.[Crossref]
  25. Nishiura H, , 2008. Duration of short-lived cross-protective immunity against a clinical attack of dengue: a preliminary estimate. Dengue Bull 32: 5566.
  26. Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkhachorn A, Mammen MP, Darunee B, Yoon IK, Endy TP, , 2014. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 209: 360368.[Crossref]
  27. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, Lim AP, Vasudevan SG, Hanson BJ, Ooi EE, , 2011. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 108: 1247912484.[Crossref]
  28. Chan KR, Ong EZ, Tan HC, Zhang SL, Zhang Q, Tang KF, Kaliaperumal N, Lim AP, Hibberd ML, Chan SH, Connolly JE, Krishnan M, Lok SM, Hanson BJ, Lin CN, Ooi EE, , 2014. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci USA 111: 27222727.[Crossref]
  29. Wu RS, Chan KR, Tan HC, Chow A, Allen JC, Jr Ooi EE, , 2012. Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. Antiviral Res 96: 340343.[Crossref]
  30. Boonnak K, Slike BM, Donofrio GC, Marovich MA, , 2013. Human FcgammaRII cytoplasmic domains ifferentially influence antibody-mediated dengue virus infection. J Immunol 190: 56595665.[Crossref]
  31. Nimmerjahn F, Lux A, , 2014. LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 111: 24042405.[Crossref]
  32. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB, , 2002. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 11: 223227.[Crossref]
  33. Tricou V, Ninh NN, Vani TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP, , 2010. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4: e785.[Crossref]
  34. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP, , 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 207: 14421450.[Crossref]
  35. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP, , 2011. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl Trop Dis 5: e1309.[Crossref]
  36. Nishiura H, Halstead SB, , 2007. Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis 195: 10071013.[Crossref]
  37. Halstead SB, , 1974. Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 23: 974982.
  38. Focks DA, Daniels E, Haile DG, Keesling JE, , 1995. A simulation model of the epidemiology of urban dengue fever: literature analysis, model development, preliminary validation, and samples of simulation results. Am J Trop Med Hyg 53: 489506.
  39. Chan M, Johansson MA, , 2012. The incubation periods of dengue viruses. PLoS ONE 7: e50972.[Crossref]
  40. Wilder-Smith A, Schwartz E, , 2005. Dengue in travelers. N Engl J Med 353: 924932.[Crossref]
  41. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A, , 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 29.[Crossref]
  42. Burke DS, Nisalak A, Johnson DE, Scott RM, , 1988. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172180.
  43. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB, , 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653669.[Crossref]
  44. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP, Jr Statler JD, Innis BL, , 2013. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 207: 700708.[Crossref]
  45. Durbin AP, Whitehead SS, , 2013. The dengue human challenge model: has the time come to accept this challenge? J Infect Dis 207: 697699.[Crossref]
  46. Thomas SJ, , 2013. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother 9: 15871590.[Crossref]
  47. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB, , 2002. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 6: 118124.[Crossref]
  48. Ooi EE, Goh KT, Chee Wang DN, , 2003. Effect of increasing age on the trend of dengue and dengue hemorrhagic fever in Singapore. Int J Infect Dis 7: 231232.[Crossref]
  49. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, Videa E, Rodriguez Y, Perez MA, Cuadra R, Solano S, Rocha J, Idiaquez W, Gonzalez A, Harris E, , 2005. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 73: 10631070.
  50. Gamble J, Bethell D, Day NP, Loc PP, Phu NH, Gartside IB, Farrar JF, White NJ, , 2000. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? Clin Sci (Lond) 98: 211216.[Crossref]
  51. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: U.S. Department of Health and Human Services.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0132
Loading
/content/journals/10.4269/ajtmh.14-0132
Loading

Data & Media loading...

  • Received : 04 Mar 2014
  • Accepted : 05 Aug 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error